Sage reported on 20th November that the EHDN-endorsed 12-week placebo-controlled, Phase 2 DIMENSION study of Sage-718 (dalzanemdor) has failed to meet its primary or secondary endpoints. Given these results, the dalzanemdor programme will close, including the currently ongoing open-label extension study PURVIEW.

While these are disappointing developments, we recognise and are grateful for the progress made by Sage in driving forward the assessment of cognition in HD.

For details of all ongoing and completed EHDN-endorsed studies, click here.